Navigation Links
Shire Proposes to Expand Specialist Gastrointestinal Portfolio
Date:8/3/2010

s to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company's Specialty Pharmaceutical and Human Genetic Therapies products, as well as the ability to secure and integrate new products for commerciali
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
2. Shire Receives CHMP Positive Opinion for VPRIV(TM) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union
3. Shire plc Appoints Two New Board Directors
4. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
5. Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection)
6. INTUNIV(TM) - Shire Files Suit Against Actavis Elizabeth LLC and Actavis Inc.
7. Shires Replenished Portfolio Drives Excellent Quarterly Performance
8. Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals
9. Shire Supports Rare Disease Day 2010
10. Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease
11. Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013  Insero Health, Inc., ... needs in epilepsy and related neurological disorders, is today ... its lead compound INS001 in patients with drug-resistant epilepsy.  ... and Device Trials (AED) Xll meeting by Dr. ... and Chairman of Insero,s Scientific Advisory Board.  In this ...
(Date:5/17/2013)... The paradigm of ‘one drug, one target’ has ... predict the adverse and therapeutic effects of a drug. ... Biology at the Genomics Laboratory, Covance, will discuss the ... when used as part of the QC process. Additionally, ... to identify key clinical targets even in complex data ...
(Date:5/17/2013)... May 17, 2013 Rust removal is one ... non-metal home items could be damaged. To help rust contractors ... of its no-scrubbing rust remover it called Rusterizer. ... available with 10% discount. , My Cleaning Products explained that ... them or by staining them. The first one, it ...
(Date:5/17/2013)... 2013 Tooth decay is an epidemic in ... of the disease. The World Health Organization says that worldwide, ... adults have cavities. What are the long-term effects of this ... strong connection between the oral bacterial imbalance and serious systemic ... rampant, yet it is also 100% preventable? Answer: there has ...
Breaking Biology Technology:Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2Organic-Based Rust Remover Cuts Down Price by 10%, My Cleaning Products Details Mechanics How to Get the Discount 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3
... & Conference Held in Pittsburgh - Over 1,000 Expected ... Attendees to Discuss New Technologies, New Business, PITTSBURGH, ... forum for the growing business of using,waste materials and ... will take place in downtown Pittsburgh,s David L. Lawrence,Convention ...
... Speaker at AdvaMed 2008 - Book signing to ... Healthcare policy,regulatory environment, elements of the global marketplace, ... 2008 MedTech Conference., Wednesday panel presentations will ... the wireless & IT sectors, remote patient monitoring,technologies, ...
... Researchers at The University of Texas at San Antonio (UTSA) ... of Texas Health Science Center at San Antonio (UTHSCSA) have ... controlling the early infectious process against Francisella tularensis, ... of tularemia. The findings will be released this week in ...
Cached Biology Technology:Former Speaker of the House Newt Gingrich Featured Wednesday 2UTSA/UTHSCSA publish results on bio-threat agent 2
(Date:5/16/2013)... (GWA), where the entirety of an individual,s DNA is ... which can cause health problems is a massively useful ... pose major ethical problems if used incorrectly, say new ... published on line today (16 May 2013) in the ... based on whole genome and on exome* sequencing and ...
(Date:5/16/2013)... 2013 Reportlinker.com announces that a ... its catalogue: Global Biometric ... http://www.reportlinker.com/p01181929/Global-Biometric-Systems-Market-Forecast--Opportunities-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Security_Systems Lack ... such as photographs, passwords and PIN codes ... in last few years. Security threats such ...
(Date:5/15/2013)... trial to date to examine the efficacy of PARP ... than breast and ovarian cancer, the oral drug olaparib ... prostate cancers. Results of the study, led by researchers ... of Pennsylvania and Sheba Medical Center in Tel Hashomer, ... Clinical Oncology,s annual meeting in Chicago in early June ...
Breaking Biology News(10 mins):European Society of Human Genetics urges caution over use of new genetic sequencing techniques 2Global Biometric Systems Market Forecast & Opportunities, 2018 2Global Biometric Systems Market Forecast & Opportunities, 2018 3Global Biometric Systems Market Forecast & Opportunities, 2018 4Global Biometric Systems Market Forecast & Opportunities, 2018 5Global Biometric Systems Market Forecast & Opportunities, 2018 6Global Biometric Systems Market Forecast & Opportunities, 2018 7PARP inhibitor shows activity in pancreatic, prostate cancers among patients carrying BRCA mutations 2
... was originally believed to be involved in tuberculosis antibiotic ... pathway for an agent used by the bacteria to ... of the Week" in the April 8 issue of ... Biochemistry and Molecular Biology journal. , Mycobacterium tuberculosis, the ...
... be brought to the marketplace, giving laboratories everywhere ... Transfer GmbH (EMBLEM), the commercial entity of the ... it has signed a licensing deal with technological ... called SPIM (Selective Plane Illumination Microscopy). , "Microscopes ...
... very special mice, scientists have discovered a new tumor ... the development of human leukemia, findings that open up ... say. , Researchers in The Ohio State University Comprehensive ... acute lymphoblastic leukemia (ALL). The mouse first goes through ...
Cached Biology News:Scientists find missing enzyme for tuberculosis iron scavenging pathway 2The transparent organism: EMBLEM and Carl Zeiss give labs a unique look at life 2Genome-wide mouse study yields link to human leukemia 2Genome-wide mouse study yields link to human leukemia 3
... are used to study co-translational and ... events such as signal peptide cleavage, ... can be examined by the translation ... in the presence of these microsomal ...
... you need to make your strain of ... Take advantage of Lucigen’s unrivalled expertise in ... Cell Service offers: Chemically competent ... Fast turnaround Quality ...
... products ATP-Free using Mo Bio luciferase assay. Mo ... service that will allow you to certify your ... and enable you to deliver them to your ... ATP detection limit is 3.5 x 10-12 /l, ...
Glucagon-like peptide-1 (GLP-1 (1-36) amide)...
Biology Products: